Aziyo Biologics Inc.

10.17-0.4200-3.97%Vol 16.47K1Y Perf -30.14%
Jun 14th, 2021 16:00 DELAYED
BID10.06 ASK11.50
Open10.53 Previous Close10.59
Pre-Market- After-Market-
 - -  - -%
Target Price
17.00 
Analyst Rating
— — 0.00
Potential %
67.16 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     38.63
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
     34.24
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap104.02M 
Earnings Rating
Price Range Ratio 52W %
9.67 
Earnings Date
3rd Aug 2021

Today's Price Range

10.0610.60

52W Range

9.3118.20

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-2.96%
1 Month
-11.57%
3 Months
-22.25%
6 Months
-24.44%
1 Year
-30.14%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AZYO10.17-0.4200-3.97
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.57-0.5012.28
Q04 2020-0.51-0.57-11.76
Q03 2020-2.37-15.79-566.24
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date3rd Aug 2021
Estimated EPS Next Report-0.55
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume16.47K
Shares Outstanding10.23M
Trades Count470
Dollar Volume230.34K
Avg. Volume20.47K
Avg. Weekly Volume22.20K
Avg. Monthly Volume27.89K
Avg. Quarterly Volume22.03K

Aziyo Biologics Inc. (NASDAQ: AZYO) stock closed at 10.17 per share at the end of the most recent trading day (a -3.97% change compared to the prior day closing price) with a volume of 16.47K shares and market capitalization of 104.02M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 163 people. Aziyo Biologics Inc. CEO is Ronald K. Lloyd.

The one-year performance of Aziyo Biologics Inc. stock is -30.14%, while year-to-date (YTD) performance is -25.39%. AZYO stock has a five-year performance of %. Its 52-week range is between 9.31 and 18.2, which gives AZYO stock a 52-week price range ratio of 9.67%

Aziyo Biologics Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 6.59, a price-to-sale (PS) ratio of 1.64, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.82%, a ROC of -51.02% and a ROE of -157.15%. The company’s profit margin is -48.86%, its EBITDA margin is -28.10%, and its revenue ttm is $45.70 Million , which makes it $6.44 revenue per share.

Of the last four earnings reports from Aziyo Biologics Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.55 for the next earnings report. Aziyo Biologics Inc.’s next earnings report date is 03rd Aug 2021.

The consensus rating of Wall Street analysts for Aziyo Biologics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Aziyo Biologics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aziyo Biologics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aziyo Biologics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 40.50, ATR14 : 0.89, CCI20 : -132.91, Chaikin Money Flow : 0.13, MACD : -0.32, Money Flow Index : 62.64, ROC : -17.59, RSI : 36.96, STOCH (14,3) : 4.18, STOCH RSI : 0.12, UO : 38.09, Williams %R : -95.82), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aziyo Biologics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Aziyo Biologics Inc.

Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

CEO: Ronald K. Lloyd

Telephone: +1 240 247-1170

Address: 12510 Prosperity Drive, Silver Spring 20904, MD, US

Number of employees: 163

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

67%33%

Bearish Bullish

67%33%

Bearish Bullish

50%50%

News

Stocktwits